Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1 1

Status

Recruiting 2

Sponsor Class

INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 2

Conditions

Breast Neoplasms 12Neoplasm Metastasis 3Stomach Neoplasms 2Endometrial Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Uterine Neoplasms 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Ovarian Neoplasms 1Neoplasms 1HER2-positive Gastric Cancer 1HER2-Positive Primary Breast Cancer 1Carcinoma, Ovarian Epithelial 1Breast Diseases 1Brain Neoplasms 1Biliary Tract Neoplasms 1Anatomic Stage IV Breast Cancer AJCC v8 1Adenocarcinoma 1

Interventions

Paclitaxel 25Doxorubicin 15Carboplatin 14pembrolizumab 10Cisplatin 8Radiotherapy 6Docetaxel 5Chemotherapy, Adjuvant 5Taxes 4Filgrastim 4Brachytherapy 4lenvatinib 3Observation 3trastuzumab deruxtecan 2selinexor 2olaparib 2durvalumab 2Tamoxifen 2Specimen Handling 2Ifosfamide 2Drug Therapy 2sintilimab 1sacituzumab govitecan 1pertuzumab 1nanocis 1liposomal doxorubicin 1ixabepilone 1gallium-diethylenetriaminepentaacetic acid-mannosyl-dextran 1dostarlimab 1atezolizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Endometrial Neoplasms × trastuzumab deruxtecan × Clear all
NCT07022483 2026-05-28

Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer

Daiichi Sankyo

Phase 3 Recruiting
710 enrolled
Gynecologic

Neoplasms, Endometrial Neoplasms

NCT06989112 2026-05-06

DE-01

AstraZeneca

Phase 3 Recruiting
600 enrolled
Gynecologic

Parkinson Disease 4, Autosomal Dominant Lewy Body, Uterine Neoplasms, Endometrial Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡